Catalyst Wire Dossier Catalyst Wire Dossier

YM155

Sepantronium bromide · Astellas Pharma Inc
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for YM155, covering 2010-04-13 to 2015-10-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study of YM155 Plus Rituximab in Subjects With Non-Hodgkin's Lymphoma Who Have Received Prior Treatment [Phase 2]

See pricing